A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study

Thrombosis Journal

Volumn 8, Issue , 2010, Pages

  Pönitz, Volker ^a,b   Govers Riemslag, José W ^c   ten Cate, Hugo ^c   van Oerle, Rene ^c   Brügger Andersen, Trygve ^a,b   Grundt, Heidi ^a,b   Næsgaard, Patrycja ^a,b   Pritchard, David ^d   Larsen, Alf I ^a,b   Nilsen, Dennis W ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Axis Shield Diagnostics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; COMPLEMENT COMPONENT C1S INHIBITOR; ENZYME PRECURSOR; KALLIKREIN INHIBITOR; TRYPSIN INHIBITOR;

ADULT; ANAMNESIS; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; LATE STENT THROMBOSIS; MALE; STENT THROMBOSIS; VERY LATE STENT THROMBOSIS;

EID: 77953347997     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-8-6     Document Type: Article

References (36)

1. Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stents. Evolving concepts and perspectives. J Am Coll Cardiol 2007, 50:119-27. 10.1016/j.jacc.2007.04.031, 17616295.
2. Bavry AA, Kumbhani DJ, Helton T, Bhatt DL. Risk of thrombosis with the use of sirolimus eluting stents for precutaneous coronaryintervention. Am J Cardiol 2005, 95:1469-72. 10.1016/j.amjcard.2005.02.015, 15950574.
3. Windecker S, Meier B. Late stent thrombosis. Circulation 2007, 116:1952-65. 10.1161/CIRCULATIONAHA.106.683995, 17965406.
4. Wenaweser P, Rey C, Eberli FR, Togni M, Tuller D, Locher S, et al. Stent thrombosis following bare-metal stent implantation: sucess of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005, 26:1180-1187. 10.1093/eurheartj/ehi135, 15728650.
5. Kuchulakanti PK, Chu WW, Torguson R, Ohlman P, Rha SW, Clavijo LC, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006, 113:1108-1113. 10.1161/CIRCULATIONAHA.105.600155, 16490815.
6. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metalstents. N Eng J Med 2007, 356:989-997.
7. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficiacy of sirolimus and paclitaxel-elutingcoronary stents. N Eng J Med 2007, 356:998-1008.
8. Kastrati A, Mehili J, Pache J, Kaiser C, Valgimigli M, Kelbaeck H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Eng J Med 2007, 356:1030-39.
9. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007, 115:2426-24. 10.1161/CIRCULATIONAHA.106.658237, 17485593.
10. Virmany R, Guaglliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 2004, 109:701-705. 10.1161/01.CIR.0000116202.41966.D4, 14744976.
11. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis. J Am Coll Cardiol 2005, 45:1753-56. 10.1016/j.jacc.2004.10.079, 15936600.
12. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202. 10.1016/j.jacc.2006.03.042, 16814667.
13. Kaplan AP, Austen KF. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 1971, 133:696-712. 10.1084/jem.133.4.696, 2138966, 4251126.
14. Murano G. The "Hageman" Connection: Interrelationships of blood coagulation, fibrino(geno)lysis, kinin generation, and complement activation. Am J Hematol 1978, 4:409-17. 10.1002/ajh.2830040412, 362910.
15. Kurachi K, Fujikawa K, Davie EW. Mechanism of activation of bovine factor XI by factor XII and factor XIIa. Biochemistry 1980, 19:1330-8. 10.1021/bi00548a011, 6155942.
16. Radcliffe R, Bangdasarian A, Colman R, Nemerson Y. Activation of bovine factor VII by hageman factor fragments. Blood 1977, 50:611-7.
17. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983, 71:1450-6. 10.1172/JCI110898, 437009, 6304147.
18. Toosi Z, Sedor JR, Mettler MA, Everson B, Young T, Ratnoff OD. Induction of expression of monocyte interleukin 1 by Hageman factor (factorXII). Proc Natl Acad Sci USA 1992, 89:11969-72. 10.1073/pnas.89.24.11969, 50679, 1465426.
19. Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M, et al. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986, 67:1731-7.
20. Wachtfogel YT, Kettner C, Hack CE, Nuijens JH, Reilly TM, Knabb RM, et al. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation. Thromb Haemost 1998, 80:686-91.
21. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-agedmen. Arterioscler Thromb Vasc Biol 1997, 17:2103-6.
22. Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, et al. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 2000, 102:2058-62.
23. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000, 102:2816-22.
24. Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction: association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998, 79:14-8.
25. Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 2004, 147:260-6. 10.1016/j.ahj.2003.07.012, 14760323.
26. Pönitz V, Brügger-Andersen T, Pritchard D, Grundt H, Staines H, Nilsen DW, . RACS Study Group Activated factor XII type A predicts long-term mortality in patients admitted with chest pain. J Thromb Haemost 2009, 7(2):277-87. RACS Study Group.
27. Govers-Riemslag JW, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, et al. The plasma kallikrein.kinin system and risk of cardiovascular disease in men. J Thromb Haemost 2007, 5:1896-1903. 10.1111/j.1538-7836.2007.02687.x, 17723129.
28. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005, 202:271-81. 10.1084/jem.20050664, 2213000, 16009717.
29. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006, 108:4045-51. 10.1182/blood-2005-12-023697, 16931632.
30. Bach J, Endler G, Winkelmann BO, Boehm W, Maerz C, Mannhalter P, et al. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C 46T gene polymorphism and coronary risk. J Thromb Haemost 2008, 6:291-6.
31. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between Factor XII activity and overall survival. J Thromb Haemost 2007, 5:1143-8. 10.1111/j.1538-7836.2007.02530.x, 17388965.
32. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials. Circulation 2007, 115:2344-2351. 10.1161/CIRCULATIONAHA.106.685313, 17470709.
33. Esnouf MP, Burgess AI, Dodds AW, Sarphie AF, Miller GJ. A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not Factor XII or complexes of Factor XIIa with C1 esterase inhibitor. Thromb Haemost 2000, 83:874-81.
34. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine high-sensitivity C-reactive protein methods. Clin Chem 2001, 47:418-25.
35. Nilsen DWT, Melberg T, Larsen AI, Barvik S, Bonarjee V. Late complications following the deployment of drug eluting stents. Int J Cardiol 2006, 109(3):398-401. 10.1016/j.ijcard.2005.05.029, 16102858.
36. Daemen J, Wenaweser P, Tsuchida K, Albrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolismus-eluting and paclitaxel-eluting stents in routine clinical pactise. Lancet 2007, 369:667-678. 10.1016/S0140-6736(07)60314-6, 17321312.